Our Science › Neurology › Parkinson’s Disease

Targeting Adenosine A2A Receptors in Parkinson’s Disease

Adenosine A2A receptor signaling counteracts dopaminergic activity in Parkinson’s disease. TT-10 is a highly selective A2A receptor antagonist designed for use with L-dopa to help restore motor signaling. TT-10 blocks A2A receptors and has longer receptor residence time that may support a more sustained therapeutic effect.

Adjunctive use with L-dopa — TT-10 is designed to complement, not replace, standard-of-care dopaminergic therapy.

Schematic showing adenosine A2A receptor antagonism in Parkinson's disease: adenosine released at the dopaminergic neuron activates A2A receptors, opposing dopaminergic signaling. TT-10 blocks A2A receptors with a longer receptor residence time, intended for use alongside L-dopa to restore motor signaling.

Mechanism Of Action

Restoring Dopamine Signaling

By blocking striatal A2A receptors, TT-10 reduces adenosine’s inhibitory effect on dopaminergic signaling. In combination with L-dopa, this mechanism is intended to enhance motor benefit.

STEP 1
Adenosine
Activates A2A receptors in the striatum
STEP 2
A2A Receptor Activation
Opposes dopaminergic signaling
STEP 3
TT-10 Blocks A2A Receptors
Reduces adenosine's inhibitory effect on dopaminergic signaling
STEP 4
Longer Binding
Longer receptor residence time may support sustained blockade
STEP 5
With L-dopa
Intended to complement L-dopa and improve motor signaling

Explore Our Pipeline

See where TT-4 and the broader Cyncado portfolio sit in clinical development.

View PipelineMesothelioma Awareness